Abstract:Nanomedicines have achieved several successful clinical applications for cancer therapy over the past decades. To date, numerous nanomedicine formats and design rationales have been proposed to improve pharmaceutical delivery and treatment efficacy. Despite these advances, the achievement of high drug loading and loading efficiencies of drug payloads in nanocarriers remains a technical challenge. In addition, study of the correlation between therapeutic potential and drug loading has been ignored. Here, using a self-assembling dimeric cabazitaxel prodrug, we show that the prodrug can be quantitatively entrapped within clinically approved polymer matrices for intravenous injection and that the drug loading in the nanoparticles (NPs) is tunable. The engineered NPs (NPs1-4) with different drug loading values exhibit dissimilar morphologies, release kinetics, in vitro cytotoxic activity, pharmacokinetic properties, tissue distribution, and in vivo anticancer efficacy and safety profiles. Furthermore, the effect of drug loading on the treatment outcomes was explored through detailed in vitro and in vivo studies. Intriguingly, among the constructed NPs, those comprising poly(ethylene glycol)-block-poly(D,L-lactic acid) (PEG-PLA) copolymers showed substantially prolonged pharmacokinetic properties in the blood circulation, which further promoted their intratumoral delivery and accumulation. Furthermore, the PEG-PLA-composed NPs with high drug loading (~50%) demonstrated favorable efficacy and safety profile in animal models. These data provide convincing evidence that the in vivo performance of a given self-assembling drug is not compromised by high drug loading in nanoplatforms, which may potentially reduce concerns over excipient-associated side effects and immunotoxicities. Overall, our study provides new insight into the rationale for designing more effective and less toxic delivery systems.

Dendritic phospholipid-based drug delivery systems

Preparation and in vitro characterization of pluronic-attached polyamidoamine dendrimers for drug delivery.

Dendritic Nanoglobules with Polyhedral Oligomeric Silsesquioxane Core and Their Biomedical Applications

Nanodelivery of a Self-Assembling Prodrug with Exceptionally High Drug Loading Potentiates Chemotherapy Efficacy.

Structural Characterization of Novel Phospholipid Lipid Nanoparticles for Controlled Drug Delivery

Supramolecularly Engineered Phospholipids Constructed by Nucleobase Molecular Recognition: Upgraded Generation of Phospholipids for Drug Delivery.

A Self-Assembling Amphiphilic Peptide Dendrimer-Based Drug Delivery System for Cancer Therapy

Effect of Lipophilic Chains on the Antitumor Effect of a Dendritic Nano Drug Delivery System

Linear–dendritic Block Copolymer for Drug and Gene Delivery

Characterization of Amphiphilic Dendrimer Modified PEG-PLA Nanoparticles Prepared by a Double Emulsion-Solvent Evaporation Method

Design and Evaluation of A Phospholipase D Based Drug Delivery Strategy of Novel Phosphatidyl-Prodrug

Synthesis, Self-Assembly, and in Vitro Doxorubicin Release Behavior of Dendron-Like/Linear/Dendron-Like Poly(Epsilon-Caprolactone)-B-Poly(Ethylene Glycol)-B-Poly(Epsilon-Caprolactone) Triblock Copolymers

Facial Solid-Phase Synthesis of Well-Defined Zwitterionic Amphiphiles for Enhanced Anticancer Drug Delivery

Non-ionic PEG-oligoglycerol dendron conjugated nano-carriers for dermal drug delivery

Dendrimer-based Multilayer Nanocarrier for Potential Synergistic Paclitaxel–doxorubicin Combination Drug Delivery

Micelles from Amphiphilic Block Copolyphosphates for Drug Delivery

Lysine and citric acid based pegylated polymeric dendritic nano drug delivery carrier and their bioactivity evaluation

New cyclodextrin derivative containing poly(L-lysine) dendrons for gene and drug co-delivery.

Dendron-Like Poly(Epsilon-Benzyloxycarbonyl-L-Lysine)/Linear Peo Block Copolymers: Synthesis, Physical Characterization, Self-Assembly, and Drug-Release Behavior

Synthesis of Degradable Bifunctional Dendritic Polymers As Versatile Drug Carriers

Preparation of New Poly(Ethylene Glycol)-Block-Dendritic Poly(L-Lysine)S Conjugated with Doxorubicin and Its Controlled Drug Release